Perioperative Systemic Therapy for Resectable Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Translational Medicine
• Clinical Trials

Background:

• Despite advances, early-stage non-small cell lung cancer (NSCLC) recurrence after resection is common.
• Immune checkpoint inhibitors and targeted therapies are emerging as potential treatments for resected NSCLC.
• Moving these therapies to the perioperative setting may improve survival outcomes.

Purpose of the Study:

• To review recent and ongoing clinical trials of neoadjuvant and adjuvant systemic therapies in NSCLC.
• To discuss the potential future directions for perioperative treatments in early-stage NSCLC.

Main Methods:

• Review of recent clinical trials (e.g., CheckMate 816, ADAURA, IMpower010) evaluating immunotherapy and targeted therapy in the perioperative setting for NSCLC.
• Analysis of ongoing neoadjuvant and adjuvant systemic therapy trials.
• Discussion of future trends in NSCLC treatment.

Main Results:

• Recent trials have led to new approvals and demonstrated the efficacy of perioperative immunotherapy and targeted therapy.
• These approaches show promise in improving survival for patients with resected NSCLC.
• Significant ongoing research is exploring these treatment modalities.

Conclusions:

• Perioperative immunotherapy and targeted therapies represent a significant advancement for early-stage NSCLC.
• Continued research and clinical trials are crucial for optimizing treatment strategies.
• The field is rapidly evolving towards incorporating systemic therapies in the curable setting for NSCLC.